Second Annual AI & Drug Discovery Symposium: Revolutionizing the Future of Medicine
Summary
Goodwin hosted our Second Annual AI & Drug Discovery Symposium at our Boston office on October 1. This event brought together leaders across life sciences, technology, and investment to discuss the opportunities and challenges shaping the next generation of AI-enabled drug discovery. Through engaging conversations and expert insights, attendees explored emerging market and investment dynamics, innovative collaboration models, regulatory and policy considerations, and approaches to creating, protecting, and maximizing value across proprietary data, intellectual property, and AI-enabled platforms in an evolving life sciences landscape.
The program concluded with a networking reception, offering attendees the opportunity to connect with fellow executives, investors, advisors, and innovators across the life sciences and technology ecosystems over drinks and light refreshments.
We invite you to explore our latest article, “Proprietary Data and Specialist AI: The Evolving Market in Life Sciences Transactions,” for additional perspectives on the opportunities and challenges facing the sector.
Session Recordings
Revisit topical conversations from the Symposium or catch up on what you missed.
Speakers
- Shane Albright
Shane Albright
Partner - Kaitlin Betancourt
Kaitlin Betancourt
PartnerCo-Chair AI - Elaine Herrmann Blais
Elaine Herrmann Blais
PartnerCo-Chair, Intellectual Property Litigation - Stuart M. Cable
Stuart M. Cable
Vice Chair & Global Head of M&A - Martin Gomez
Martin Gomez
Partner - Elizabeth Mulkey
Elizabeth Mulkey
Partner - Erini R. Svokos
Erini R. Svokos
Partner - Joseph C. Theis Jr.
Joseph C. Theis Jr.
PartnerLeader, Corporate and Transactional - Bethany P. Withers
Bethany P. Withers
PartnerCo-Chair, AI